Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
6.59 USD
65.07 M USD
122.83 M USD
9.32 M
About SANTHERA N
Sector
CEO
Dario Eklund
Headquarters
Pratteln
Website
Founded
1998
ISIN
CH1276028821
FIGI
BBG000RRKS06
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. Its product pipeline includes Vamorolone and Lonodelestat. The company was founded by Thomas Meier in 1998 and is headquartered in Pratteln, Switzerland.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of SPHDF is 11.70 USD — it has increased by 4.00% in the past 24 hours. Watch Santhera Pharmaceuticals Holdings Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Santhera Pharmaceuticals Holdings Ltd. stocks are traded under the ticker SPHDF.
We've gathered analysts' opinions on Santhera Pharmaceuticals Holdings Ltd. future price: according to them, SPHDF price has a max estimate of 28.83 USD and a min estimate of 23.07 USD. Watch SPHDF chart and read a more detailed Santhera Pharmaceuticals Holdings Ltd. stock forecast: see what analysts think of Santhera Pharmaceuticals Holdings Ltd. and suggest that you do with its stocks.
SPHDF reached its all-time high on Sep 21, 2015 with the price of 1,371.50 USD, and its all-time low was 6.80 USD and was reached on Apr 3, 2023. View more price dynamics on SPHDF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
SPHDF stock is 3.85% volatile and has beta coefficient of 0.14. Track Santhera Pharmaceuticals Holdings Ltd. stock price on the chart and check out the list of the most volatile stocks — is Santhera Pharmaceuticals Holdings Ltd. there?
Today Santhera Pharmaceuticals Holdings Ltd. has the market capitalization of 113.56 M, it has increased by 1.63% over the last week.
Yes, you can track Santhera Pharmaceuticals Holdings Ltd. financials in yearly and quarterly reports right on TradingView.
Santhera Pharmaceuticals Holdings Ltd. is going to release the next earnings report on Apr 24, 2025. Keep track of upcoming events with our Earnings Calendar.
Santhera Pharmaceuticals Holdings Ltd. revenue for the last half-year amounts to 15.68 M USD, despite the estimated figure of 6.23 M USD. In the next half-year revenue is expected to reach 15.45 M USD.
SPHDF net income for the last half-year is −16.98 M USD, while the previous report showed 92.78 M USD of net income which accounts for −118.30% change. Track more Santhera Pharmaceuticals Holdings Ltd. financial stats to get the full picture.
No, SPHDF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 44.00 employees. See our rating of the largest employees — is Santhera Pharmaceuticals Holdings Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Santhera Pharmaceuticals Holdings Ltd. EBITDA is 63.48 M USD, and current EBITDA margin is 51.81%. See more stats in Santhera Pharmaceuticals Holdings Ltd. financial statements.
Like other stocks, SPHDF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Santhera Pharmaceuticals Holdings Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Santhera Pharmaceuticals Holdings Ltd. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Santhera Pharmaceuticals Holdings Ltd. stock shows the sell signal. See more of Santhera Pharmaceuticals Holdings Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.